Pharmaceutical Technology6m
Risk adjusted net present value: What is the current valuation of Otsuka’s Zipalertinib?
The revenue for Zipalertinib is expected to reach an annual total of $47 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology10m
Risk adjusted net present value: What is the current valuation of Roche’s RG-6641?
RG-6641 is a synthetic peptide commercialized by Roche, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ...
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Zilganersen Sodium?
Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, ...
Pharmaceutical Technology17m
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s Apinocaltamide?
The revenue for Apinocaltamide is expected to reach an annual total of $430 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology22m
Risk adjusted net present value: What is the current valuation of Replimune’s Vusolimogene Oderparepvec?
The revenue for Vusolimogene Oderparepvec is expected to reach an annual total of $29 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs ...
Pharmaceutical Technology24m
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Mazisotine?
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
Pharmaceutical Technology24m
Risk adjusted net present value: What is the current valuation of Cogent Biosciences’s Bezuclastinib?
Bezuclastinib is a small molecule commercialized by Cogent Biosciences, with a leading Phase III program in Gastrointestinal Stromal Tumor (GIST).
Pharmaceutical Technology28m
Risk adjusted net present value: What is the current valuation of Ono Pharmaceutical’s Vimseltinib?
Vimseltinib is a small molecule commercialized by Ono Pharmaceutical, with a leading Pre-Registration program in Tenosynovial Giant Cell Tumor.
Pharmaceutical Technology28m
Risk adjusted net present value: What is the current valuation of Immunome’s AL-102?
AL-102 is a small molecule commercialized by Immunome, with a leading Phase I program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma.
Pharmaceutical Technology33m
Risk adjusted net present value: What is the current valuation of Oryzon Genomics’s Iadademstat?
Iadademstat is a small molecule commercialized by Oryzon Genomics, with a leading Phase II program in Neuroendocrine Carcinoma.